ESSA Pharma Inc.:
IND 1Q2020. Developing small molecule drugs for the treatment of CRPC. Lead asset selectively blocks the n-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Preclincial data packet shows a favorable PK profile + exhibits significant exposure potential with a long half-life. Cash into 2023.
100MM - 500MM
999 West Broadway Street Suite 720
Vancouver, British Columbia BC V5Z 1K5
Top 10 Holders of ESSA Pharma Inc
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by